Article
Immune response and resistance of clear cell renal cell carcinoma patients following immune checkpoint blockade
2023-10-08
Abstract excerpt
175,000 patients die because of renal cell carcinoma (RCC) each year. Clear cell renal cell carcinoma (ccRCC or KIRC) is the most frequent subtype of RCC. Current therapies include immune checkpoint inhibitors (ICB) or VEGFR tyrosine kinase inhibitors (TKIs). However, many patients did not respond to ICB and immune resistance still occurred. Immune resistance may be explained by expression of various immune checkp...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 0dcf7da3-4796-5ef6-9f70-6c198e45425b
- DOI
- 10.1101/2023.10.05.561140
